A method to study drug concentration-depth profiles in tissues: mitomycin C in dog bladder wall
- PMID: 1902562
- DOI: 10.1023/a:1015827700904
A method to study drug concentration-depth profiles in tissues: mitomycin C in dog bladder wall
Abstract
Determination of the depth of penetration of locally applied drug therapy and evaluation of possible mechanisms of drug transport require knowledge of drug concentration-versus-tissues depth profiles. A method to determine the drug concentration-depth profile is needed. We have devised such a method and used it to determine the penetration of mitomycin C (MMC) in the dog bladder wall after intravesical drug instillation. This method is based on sectioning of frozen tissue into 40-microns segments, followed by drug extraction and high-pressure liquid chromatography analysis. Tissue concentrations could be detected with a sensitivity of 1 ng/sample, or 20 ng/g for tissue samples of approximately 2 x 2 cm. This sensitivity was sufficient to describe the penetration of MMC in the bladder wall of dogs, using an identical instillation technique, dwell time, and MMC concentration as in human patients. Tissue concentrations were expressed relative to tissue weight or tissue protein contents. For MMC, standardization to tissue weight yielded a better mathematical fit of the concentration-versus-depth profiles than standardization to protein content. The time interval between tissue harvesting and freezing was critical. The MMC concentration at the urothelial side of dog bladders was 2- to 10-fold higher in samples processed immediately after harvesting, compared to samples processed after 1 hr or longer. This significant decrease was not due to drug metabolism in situ. In separate in vitro experiments, we found that the degradation of MMC in 8% tissue homogenate was relatively slow, with only a 30% decline in concentration over 24 hr.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Bladder wall penetration of intravesical mitomycin C in dogs.Cancer Res. 1991 Aug 15;51(16):4347-54. Cancer Res. 1991. PMID: 1907883
-
Penetration of mitomycin C in human bladder.Cancer Res. 1993 Jul 15;53(14):3314-20. Cancer Res. 1993. PMID: 8324743
-
Bladder tissue uptake of mitomycin C during intravesical therapy is linear with drug concentration in urine.Clin Cancer Res. 1998 Jan;4(1):139-43. Clin Cancer Res. 1998. PMID: 9516962
-
Mitomycin C for the treatment of bladder cancer.Minerva Urol Nefrol. 2010 Jun;62(2):133-44. Minerva Urol Nefrol. 2010. PMID: 20562793 Review.
-
Intravesical electro-osmotic administration of mitomycin C.Urologia. 2016 Oct 4;83(Suppl 2):18-23. doi: 10.5301/uro.5000202. Epub 2016 Oct 1. Urologia. 2016. PMID: 27716887 Review.
Cited by
-
Intraperitoneal therapy for peritoneal cancer.Future Oncol. 2010 Oct;6(10):1625-41. doi: 10.2217/fon.10.100. Future Oncol. 2010. PMID: 21062160 Free PMC article. Review.
-
Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer.Cancer Chemother Pharmacol. 1993;32(4):255-62. doi: 10.1007/BF00686169. Cancer Chemother Pharmacol. 1993. PMID: 8324866
-
Penetration kinetics of 2',3'-dideoxyinosine in dermis is described by the distributed model.Pharm Res. 1995 Jan;12(1):108-12. doi: 10.1023/a:1016298906589. Pharm Res. 1995. PMID: 7724469
-
Local Drug Delivery in Bladder Cancer: Advances of Nano/Micro/Macro-Scale Drug Delivery Systems.Pharmaceutics. 2023 Dec 3;15(12):2724. doi: 10.3390/pharmaceutics15122724. Pharmaceutics. 2023. PMID: 38140065 Free PMC article. Review.
-
Paclitaxel gelatin nanoparticles for intravesical bladder cancer therapy.J Urol. 2011 Apr;185(4):1478-83. doi: 10.1016/j.juro.2010.11.091. Epub 2011 Feb 19. J Urol. 2011. PMID: 21334664 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources